Abstract: Certain embodiments are directed to compositions and methods for attenuating allergic responses in a subject.

Abstract: The invention is related to medical and biological applications and is intended to prevent and treat coronavirus infections by applying phthalhydrazide derivatives, including Tamerit, with immunomodulatory activity independently or in combination with antiviral drugs of different chemical structure. A method for the prevention of coronavirus infection is presented, characterized by the fact that to increase the clinical and laboratory efficacy achieved by antiviral agents of the azoloazine series (Triazavirin®, Maktavirin®), antimalarials and preparations of interferon, in combination with the above preparations a preparation of aminophthalhydrazide derivatives salt, in the form of dihydrate, monohydrate, anhydrate, in any crystalline form, including Tamerit, in a dose from 0.01 to 4000 mg/kg to a subject in need is used.

Abstract: The present disclosure relates to a vaccine composition, comprising a recombinant lipidated FLIPr (rLF), and the use thereof in enhancing humoral and cellular immune responses. The recombinant lipidated FLIPr of present invention may be used as a vaccine candidate that can induce anti-FLIPr responses to overcome FLIPr-mediated inhibition. And unexpectedly, the recombinant lipidated FLIPr may be used as an adjuvant that can enhance other vaccine immune responses, especially in subunit vaccines and inactivated virus vaccines.

Abstract: The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. The invention also provides methods for treating or delaying progression of rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) in an individual. In some embodiments, the methods comprise administering an effective amount of an anti-CD20 antibody.

Abstract: Described herein are methods, formulations and kits for treating a patient with cancer with anti-VEGF antibodies and albumin-bound chemotherapeutic/anti-VEGF antibody nanoparticle complexes.

Abstract: The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.

Abstract: The present invention has designed and produced a family of recombinant proteins that could provide broad-spectrum protection/neutralization against most subtypes of TcdB, and therefore could be developed into therapies against GDI. The designs of these novel proteins are based on the first 3D structure of TcdB1 in complex with its receptor CSPG4 that was recently determined. The present invention demonstrates that these newly designed proteins are more potent and provide broader-spectrum protection than the commercial antibody bezlotoxumab in terms of neutralizing diverse subtypes of TcdB.

Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

Abstract: N(57) Abstract: There is a need for new and alternative options for immune therapy of proliferative diseases such as cancer. This need C\11 may be address by providing a chimeric antigen receptor having an extracellular domain including a binding domain which recognises Nthe cancer-stem-cell-associated protein Lgr5; a transmembrane domain; and an intracellular signalling domain that activates a cellular .,, function. Such CAR T cells can be used to kill cancer cells and treat or prevent cancer in a subject.

Abstract: The disclosure relates to chimeric antigen receptors and immune effector cells bearing chimeric antigen receptors (CARs). Disclosed herein are improved CARs that are able to recruit Lck and/or and PLC? without the need to express CD2, thereby providing efficient CAR function without the risk of CD2-induced fratricide; optionally, the CARs also comprise CD132. Further disclosed herein are improved CARs specific for CD2. Further disclosed herein are improved immune effector cells bearing such improved CARs, therapeutic compositions comprising such improved immune effector cells, and methods for treating cancer using such improved immune effector cells and/or therapeutic compositions.

Abstract: This disclosure provides methods for treating a B-cell lymphoma, by administering a CD 19 CAR therapy as described herein, in combination with a BCL2 inhibitor as described herein.

Abstract: Antigen binding agents (e.g., single domain antibodies) that bind guanylyl cyclase C (GCC) are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the antibodies and antigen-binding molecules provided herein.

Abstract: The present invention relates to a compound comprising a cisplatin component and a eugenol component. The present invention further relates to a synthesis method of said compound, pharmaceutical compositions comprising the compound and its medical uses. The present invention further relates to a method of treatment of cancer.

Abstract: Provided is a novel drug modality which at least partially overcomes the shortcomings of the conventional covalent drugs. A neutralizable covalent drug compound comprising a nucleic acid aptamer and a fluorosulfonyl group linked to the nucleic acid aptamer via a linker is provided. A composition comprising the compound and a method of producing the compound are also provided. Also provided is a neutralizable covalent drug system, comprising the compound or the composition and an oligonucleotide complementary to the nucleic acid aptamer.

Abstract: A construct includes a core comprising an external surface and a plurality of pores, a cargo disposed in a pore of the plurality of pores, the cargo comprising a CRISPR Cas9 component or a nucleic acid sequence encoding a CRISPR Cas9 component; and a coating coupled to the core, wherein the coating comprises a cationic lipid, a pegylated lipid, a zwitterionic lipid, and a sterol. The coating may comprise a molar ratio of about 1 cationic lipid to 1 zwitterionic lipid to 0.9 sterol to 0.15 PEGylated lipid, wherein each molar ratio optionally varies by about plus or minus 10%. A method of treatment is also provided.

Abstract: The present invention relates to small molecule compounds that allosterically inhibit ALC1 (CHD1L) and which induce the trapping of PARP1, PARP2 and/or PARP3 on chromatin or at DNA damage sites. Disruption of the chromatin remodeling forces of ALC1 through these agents enables a highly selective therapy for targeting the DNA damage functions of PARP enzymes in several proliferative diseases, notably BRCA-deficient cancers. Via inhibition of the enzymatic activity, the compounds engage the synthetic lethality between BRCA1/2 and ALC1. By trapping PARP enzymes, inhibitors of ALC1 potentiate the cancer cell killing properties of PARP inhibitors, enable therapeutic approaches where ALC1 is amplified as an oncogene, therapeutically make it possible to overcome PARP inhibitor resistance mechanisms and enable an alternative approach to the treatment of germline or acquired BRCA1/BRCA2 deficiency, including tumors defined by “BRCAness” or other changes in DNA repair networks.

Abstract: The present invention relates to a polyplex for use in the treatment of castration resistant prostate cancer (CRPC) comprising a double stranded RNA (dsRNA) and a polymeric conjugate, wherein said polymeric conjugate consists of a linear polyethyleneimine (LPEI), one or more polyethylene glycol (PEG) moieties, one or more linkers and one or more targeting moieties, wherein said LPEI is covalently bound to one or more PEG moieties and each of said one or more PEG moieties is conjugated via one of the one or more linkers to one of the one or more targeting moieties, wherein each of said one or more targeting moieties is capable of binding to a cancer antigen, and wherein said cancer antigen is prostate surface membrane antigen (PSMA). Further, the invention relates to a pharmaceutical composition for use in the treatment of CRPC.

Abstract: Described are the compounds, compositions and methods of treating diseases and disorders characterized by Formyl Peptide Receptor 1 (FPR1) or FPR2 activity.

Abstract: Modified monomers of a Shiga toxin B-subunit (STxB) protein including at least one of: an addition of a reactive unnatural amino acid residue at the C-terminal extremity, and/or a substitution with a reactive unnatural amino acid residue at an amino acid position among Asp 3, Lys 8, Glu 10, Tyr 11, Lys 23, Lys 27, Thr 49, Lys 53, His 58, Asn 59, and Arg 69, reference made to the numbering of STxB from Shigella dysenteriae. Also relates to STxB conjugates, and oligomers, in particular pentamers, of these modified STxB proteins and STxB conjugates; as well as to compositions including the same and their use in treatment, vaccination and diagnosis methods.

Abstract: The present invention relates generally to glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a spacer containing ((2-oxoethyl)thio)). In an aspect the invention provides oxo-eT linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a ((2-oxoethyl)thio) spacer having the formula (I): wherein: A is a group (C?X)m wherein X is S or O and m is 0 or 1; B is a bond, O, or CH2; and when m is 0, B can also be (C?O); R is a C2-C16 alkylene, C2-C16 heteroakylene, NH—C(?O)—C2-C16 alkylene, or NH—C(?O)—C2-C16 heteroakylene, wherein said alkylene and heteroalkylene are optionally substituted by 1, 2 or 3 groups independently selected from COOR? where R? is selected from H, methyl, ethyl or propyl. The invention further relates to immunogenic compositions comprising such glycoconjugates, and to methods for the preparation and use of such glycoconjugates and immunogenic compositions.

Abstract: The disclosure relates to a preparation and purification method for an antibody drug conjugate intermediate, and more particularly relates to a preparation and purification method for a linker part and drug part conjugate in an antibody drug conjugate, which can not only effectively remove impurities from a target product and by-products in a reaction process, making the purity of the target product finally obtained up to 99% or above, but also realize stable mass production and well meet the quality standard requirements of clinical drugs, so as to provide a tremendous guarantee for drug safety and stable supply.

Abstract: Provided are novel anti-CD228 antibodies and antibody-drug conjugates and methods of using such anti-CD228 antibodies and antibody-drug conjugates to treat cancer.

Abstract: The invention provides immunoconjugates of Formula I comprising an anti-PD-L1 antibody linked by conjugation to one or more 8-Cyc-2-aminobenzazepine derivatives. The invention also provides 8-Cyc-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

Abstract: Therapeutic combinations of immunoconjugates that bind to CD123 (e.g., IMGN632) with BCL-2 inhibitors (e.g., venetoclax), and/or a hypomethylating agent (e.g., azacitidine or decitabine) are provided. Methods of administering the combinations to treat hematological malignancies with clinical efficacy and/or decreased toxicity are also provided. Methods of treating hematological malignances present as minimal residual disease using immunoconjugates that bind to CD123 (e.g., IMGN632) are also provided.

Abstract: The present disclosure provides, inter alia, multi-drug Antibody Drug Conjugates (MD-ADCs) and Linking Assembly (LA) Units that are constructed in a site-specific matter via “orthogonal” deprotection and drug loading. Also provided are, Protected Linking Assembly Units, which allow for ‘orthogonal’ deprotection and construction of MD-ADCs and LA Units of the present disclosure.

Abstract: Provided herein are nanoparticles to encapsulate therapeutic agents and methods of use thereof for intracellular delivery and disease treatment. In particular, the present disclosure provides polymersomes for use in the delivery of therapeutic agents, e.g. stapled peptides, to diseased (e.g. cancer) cells.

Abstract: The present disclosure provides a nano-structural protein degradation tool, use, and a preparation method thereof, wherein the nano-structural protein degradation tool comprises: one of or a combination of several of a first degradation tool, a second degradation tool, and a third degradation tool, wherein the first degradation tool is formed by linking POI recognition groups to linkers; the second degradation tool is formed by linking the POI recognition groups to nanoparticles; and the third degradation tool is formed by linking the POI recognition groups to the nanoparticles through the linkers. The present disclosure further provides a lipid-based protein degradation tool, use, and a preparation method thereof, wherein the lipid-based protein degradation tool comprises: POI recognition groups, and lipid hybrid substances linked to the POI recognition groups.

Abstract: Compositions useful for treatment of Spinal and Bulbar Muscular Atrophy (SBMA) comprising administration of a recombinant adeno-associated virus (rAAV) vector having an AAV capsid and a vector genome comprising a sequence encoding at least one hairpin forming miRNA that comprises a targeting sequence which binds a target site on the mRNA of human androgen receptor, wherein the miRNA inhibits expression of human androgen receptor, is provided. Also provided are compositions containing a rAAV vector and methods of treating SBMA in patient comprising administration of a rAAV vector.

Abstract: The present invention provides compositions, systems, kits, and methods for expression of one or more biomolecules in a subject, human or non-human mammal, (e.g., at therapeutic levels for the extended periods of time required to produce therapeutic effects). In certain embodiments, compositions, systems, kits, and methods are provided that comprise a first composition comprising polycationic structures (e.g., empty cationic liposomes, cationic micelles, cationic emulsions, or cationic polymers) and a second composition comprising expression vectors (e.g., non-viral expression vectors not associated with liposomes or other carriers) encoding one or more biomolecules of interest.

Abstract: Provided herein polynucleotides configured for incorporation into recombinant adeno-associated virus (AAV) vectors. The polynucleotides encode for CRISPR proteins, gRNA, and ancillary components of AAV vectors useful in the modification of target nucleic acids. The systems are also useful for introduction into cells, for example eukaryotic cells having mutations in the target nucleic acid of a gene. Also provided are methods of using such AAV vectors to modify cells having such mutations.

Abstract: Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency.

Abstract: The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using thereof.

Abstract: Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a detectable target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.

Abstract: A method for fluorescent imaging of a subject, the method having the steps of: placing an illuminator in a surgical area of a subject, the illuminator having an emission band substantially similar to an fluorescence imaging agent; administering the fluorescence imaging agent to the subject; acquiring a plurality of images of the surgical area of the subject showing fluorescence intensity over a predetermined time period; and analyzing the plurality of images to determine changes in sensed fluorescence from the fluorescence imaging agent; wherein an exposure gain is applied to the images based on changes in detected intensity of the fluorescence from the illuminator.

Abstract: A means of reducing bioburden in cyclic lipopeptide compound products by a simple operation without impairing their quality or function is provided. A method for reducing bioburden of a cyclic lipopeptide compound is characterized by irradiating a cyclic lipopeptide compound with a radiation beam. A method for producing a cyclic lipopeptide compound with reduced bioburden includes irradiating a cyclic lipopeptide compound with a radiation beam.

Abstract: A disinfection system for a vehicle includes a a first light source for an interior of the vehicle for generating radiation in the UV-B and/or UV-C range and a second light source for generating radiation in the UV-C range. Whether the first or second light source is used to disinfect the interior of the vehicle depends on whether or not there is an occupant in the vehicle.

Abstract: The disclosure relates to a radiation device for disinfecting dentistry equipment, comprising a radiation chamber having at least an opening for loading and unloading the radiation chamber and a placement position for the dentistry equipment to be disinfected, disposed in the center of the radiation chamber, a door for closing the opening of the radiation chamber and at least one radiation source, in particular at least two radiation sources, each having a plurality of UVC LEDs arranged on at least two different, in particular opposite, sides of the radiation chamber. The radiation device includes four or more sensors for radiation detection, which are provided for measuring the radiation inside the radiation chamber, with at least one sensor provided in each of different edge portions of the radiation chamber.

Abstract: A sterilization system includes a vial, a carrier of microorganisms disposed in the vial, and a fluid management system having an output connectable to the vial for delivering a liquid chemical sterilant and a neutralizer thereto. Additionally, a growth medium may be delivered to the vial such that the vial and growth medium may assessed for a change to a visual characteristic indicative of sterilization inefficacy.

Abstract: Disclosed is a disinfection arrangement (100) for disinfecting a chamber (132). The disinfection arrangement (100) includes an oxygen generation chamber (109) containing a mist generator (110) and a UV-C light source (118) positioned at an outlet of the oxygen generation chamber (109). The oxygen generation chamber (109) is configured to receive hydrogen-peroxide (H2O2) such that the received (H2O2) is exposed to the UV-C light source (118) at the outlet of the oxygen generation chamber (109) to convert the H2O2 into ozone for supplying the ozone to the chamber (132).

Abstract: Embodiments disclosed include autonomous robotic systems and methods for disinfecting an environment. An autonomous disinfecting system comprises, in a housing, a first unit comprising a first plurality of UV-C lamps attached to a first wireless base comprising a plurality of wheels. Preferably, the first unit further comprises a docking port for a second unit comprising a second plurality of UV-C lamps attached to a second wireless base, and a motion sensor configured to send a signal to a processing unit comprised in the autonomous disinfecting system wherein the processing unit is configured to shut down the system when it receives a signal indicating a detected movement.

Abstract: Disclosed is a fluid interception device for a cleaning and disinfecting system for medical devices, equipped with a processing chamber, including a hollow box-shaped condenser body, including: a transit port, in fluid communication with a transit duct of the cleaning and disinfecting system; and a vent port in communication with the external environment. The hollow box-shaped condenser body includes: condensation nozzles, in fluid communication with drain holes in a lower portion of the hollow box-shaped condenser body; and water feeding nozzles, above and in fluid communication with the transit port. Between the condensation nozzles and water feeding nozzles, a separation septum being arranged which defines and divides a condensation chamber and a feeding chamber. The transit port is arranged on the side of the feeding chamber and the separation septum providing at least one flow port which places the transit port in communication with the condensation chamber.

Abstract: The present invention relates to the detection vapor peracetic acid and hydrogen peroxide. It finds particular application in the sensing of vapor peracetic acid and hydrogen peroxide concentrations. The system includes (a) a source of peracetic acid vapor, hydrogen peroxide vapor, water vapor and acetic acid vapor, (b) a light source which is configured to supply light with at least a component in the mid-infrared range, and (c) a detector which is configured to individually detect mid-infrared range light in (i) a first mid-infrared spectrum absorbed by the peracetic acid vapor and not absorbed by the hydrogen peroxide vapor, the acetic acid vapor or the water vapor, and (ii) a second mid-infrared spectrum absorbed by the peracetic acid vapor and the hydrogen peroxide vapor.

Abstract: A volatile composition dispenser includes a housing having an aperture and having opposing first and second walls that are joined along their peripheries to one another, where said second wall has a plurality of apertures; a volatile composition cartridge disposed within the housing between said first and second walls; and a gap, which exists between said volatile composition cartridge and a bottom surface of the housing, wherein said bottom surface is formed from a base portion of one or both of the first and second walls. Upon activation, the exposure percentage is greater than 40%.

Abstract: A portable air treatment system configured to be carried by an individual and deliver air, via a mask, to the individual, is provided. The system includes an air inlet allowing atmospheric air to enter at an air flow rate ranging between 2 liters/min to 10 liters/min, an air compression system connected with the air inlet for compressing the incoming air, thereby increasing the temperature of the air to a minimum temperature of 170° C., a hot air chamber connected with the air compression system for receiving the heated air from the air compression system and retaining the heated air for a period of 30-100 milliseconds, an air decompression system connected with the heated air chamber for expanding the heated air thereby decreasing the temperature of the heated air to a temperature ranging between 14° C. to 45° C., and an air outlet connected with the air expansion system for directing the cooled air to the individual via the mask.

Abstract: The high-temperature pathogen-disinfecting air filter includes a first layer of heated open-cell foam contained in a housing with an air pump configured to direct airflow across thereof. The first layer of the open-cell foam may be made of a metal alloy and includes a first electrically-resistive elongated body folded in a serpentine pattern. The pattern may define a sheet-like construction of the first layer making it convenient to incorporate into the air filter housing. The controller is provided to apply electrical energy to heat up the foam to a predetermined temperature, thereby providing heat to disinfect the airflow passing across the first layer. Additional foam layers and heat-resistant filters may also be provided.

Abstract: A light and sanitization system disclosed herein includes a housing, a ring shaped FAR-UVC emitter configured in the housing, a second light source disposed in the housing and located such that light from the second light source passes through a center of the ring shaped FAR-UVC emitter, and a power source for driving emission of UVC light from the ring shaped FAR-UVC emitter.

Abstract: Purified air is provided, having a TVOC content of from less than 5 ppb to about 500 ppb, a Biologicals content of from less than 1 CFU/M3 to 150 CFU/M3 and a Particulate content of from about 1,000 0.3 ?m particles per ft3 to about 50,000 0.3 ?m particles per ft3, or from about 600 0.5 ?m particles per ft3 to about 500,000 0.5 ?m particles per ft3.

Abstract: An air sterilisation unit comprising a housing providing an air inlet and an air outlet and containing a filter module located between the air inlet and the air outlet, a UV-C treatment chamber located between the air inlet and the air outlet and containing at least one UV-C radiation source, and a ventilation system located between the air inlet, through the filter module and the UV-C treatment chamber and out of the housing through the air outlet, wherein the UV-C treatment chamber comprises an inlet end, an outlet end and a wall there between and the inlet end is closed with a first expanded polytetrafluoroethylene filter, the outlet end is closed with a second expanded polytetrafluoroethylene and the wall is provided with an expanded polytetrafluoroethylene liner, such that the UV-C radiation source is surrounded with expanded polytetrafluoroethylene for reflection of UV-C radiation within the chamber for destruction of pathogens in the air.

Abstract: A centrifugal fan for a heating, ventilation, air conditioning, and refrigeration (HVACR) system is disclosed. The centrifugal fan includes a volute housing having an inner surface and a curved inlet shroud. The volute housing defines an air outlet. The curved inlet shroud defines an air inlet. The air inlet has an inlet airflow cross-sectional area that lies substantially perpendicular to an outlet airflow cross-sectional area of the air outlet. The centrifugal fan also includes an impeller mounted for rotation about a rotational axis within the volute housing. The impeller has a plurality of fan blades. The plurality of fan blades has an outer surface. The centrifugal fan further includes a light source. The inner surface of the volute housing and the outer surface of the plurality of fan blades includes a photocatalyst layer. The light source is configured to emit light on the photocatalyst layer.

Abstract: The present disclosure relates to a herbal bioactive dressing for healing wounds and a method thereof. The dressing includes an outer layer having a matrix of nanofibre formed by mixing cow urine with extracts obtained from Aloe Vera, Calandula, Curcumin, Sandal wood in same amount and a self-adhesive inner layer. The dressing incorporated into the nanofiber patches through electrospinning.